<5,6-Dihydroxy-indolyl-(3)>-essigsaeure | 67615-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: <5,6-Dihydroxy-indolyl-(3)>-essigsaeure
• 英文别名: 2-(5,6-Dihydroxy-1H-indol-3-yl)acetic acid
• CAS: 67615-73-0
• 化学式: C₁₀H₉NO₄
• 分子量: 207.186
• InChiKey: YYHSCOVZMMVYAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  93.6
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
  申请人：PROMETHEUS BIOSCIENCES, INC.

  公开号：US11136386B2

  公开（公告）日：2021-10-05

  Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

  本文提供的方法、系统和试剂盒用于根据是否存在与对治疗剂的阳性治疗反应相关的基因型，选择患者接受治疗剂的治疗。在某些实施方案中，治疗剂是 TL1A 活性或表达的抑制剂，例如抗 TL1A 抗体。
• TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES
  申请人：Prometheus Biosciences, Inc.

  公开号：US20200362025A1

  公开（公告）日：2020-11-19

  Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
• METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES
  申请人：CEDARS-SINAI MEDICAL CENTER

  公开号：US20210277477A1

  公开（公告）日：2021-09-09

  Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.
• [EN] TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES<br/>[FR] MÉTHODES, SYSTÈMES ET DISPOSITIFS DE SÉLECTION DE PATIENT TL1A
  申请人：PROMETHEUS BIOSCIENCES INC

  公开号：WO2020232125A1

  公开（公告）日：2020-11-19

  Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.